4.1 Article

Correlation of 18F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer

Journal

NUCLEAR MEDICINE COMMUNICATIONS
Volume 30, Issue 11, Pages 831-837

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MNM.0b013e32832dcfc4

Keywords

CD34; Ki67; non-small-cell lung cancer; positron emission tomography; standardized uptake value; survivin

Ask authors/readers for more resources

Purpose This work investigates the correlation between positron emission tomography (PET) images and the expressions of survivin, Ki67, and CD34, as well as the clinicopathological characteristics of non-small-cell lung cancer (NSCLC). Methods Thirty-three NSCLC cases were scanned with F-18-fluorodeoxyglucose (F-18-FDG), PET before surgery. Tumor resections were used to evaluate the expressions of survivin, Ki67, and CD34 by immunohistochemical assay. Maximum standardized uptake value (SUVmax), immunohistochemical results, as well as clinicopathological characteristics in NSCLC were compared and analyzed. Results The average SUVmax for the 33 NSCLC was 10.5 +/- 5.4. The expressions of survivin and Ki67 were 84.8% (28 of 33) and 72.7% (24 of 33), respectively. The median count of microvasculature vessel density labeled by CD34 was 24.5 +/- 6.7 In the entire group, SUVmax was significantly correlated to Ki67, histological type, as well as clinical type (P=0.010, 0.048, 0.029, respectively). It revealed a median survival of 33 +/- 0.6 months for SUVmax below 11 versus a median survival of 27 +/- 1.3 months for SUVmax values above 11 (P=0.013). There were no significant correlations between SUVmax and expressions of survivin and CD34, and no correlations involving age, sex, differentiation, tumor node metastasis stage, and lymph node metastasis. Conclusion SUV-indexed FDG metabolic activity correlated significantly with proliferative activity (Ki67 expression) as well as the histological and clinical tumor type. These biological predictive markers combined with F-18-FDG PET might provide more useful information on the diagnosis and prognosis of patients with NSCLC. These conclusions require confirmation with further studies. Nucl Med Commun 30:831-837 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available